UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 9, 2007
ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-21696 22-3106987
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
26 Landsdowne Street, Cambridge, Massachusetts 02139
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 494-0400
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 Other Events.
In a press release dated July 9, 2007, ARIAD Pharmaceuticals, Inc.
("ARIAD") announced that Judge Rya W. Zobel of the United States District
Court for the District of Massachusetts has found in favor of ARIAD and its
co-plaintiffs in their lawsuit against Eli Lilly and Company ("Lilly")
alleging infringement of the plaintiffs' pioneering U.S patent covering
methods of treating human disease by regulating NF-(kappa)B cell-signaling
activity. The Judge's opinion found that the patent is valid and
enforceable and that judgment may be entered for the plaintiffs in
accordance with the verdict of the jury and the Court's findings of fact
and conclusions of law.
ARIAD also announced today that the U.S. Patent and Trademark Office issued
a final Office action in its reexamination of the NF-(kappa)B patent (U.S.
Patent No. 6,410,516) and rejected the patentability of certain claims of
the patent, including those claims being asserted in the Lilly lawsuit and
a separate lawsuit against Amgen, Inc. and Wyeth. ARIAD plans to respond to
this Office action promptly and, if necessary, appeal the decision through
all appropriate means of review within the Patent Office and the courts.
The NF-(kappa)B patent remains valid and enforceable through the appeals
process. The Company estimates that the entire appeals process relating to
the reexamination may take approximately two years, or longer.
A copy of the press release is filed herewith as Exhibit 99.1 and the
information contained therein is incorporated by reference into this Item
8.01 of this Current Report on Form 8-K.
ITEM 9.01 Financial Statements and Exhibits.
(c) The following exhibits are filed with this report
Exhibit
Number Description
------ -----------
99.1 Press release dated July 9, 2007
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ARIAD Pharmaceuticals, Inc.
By: /s/ Edward M. Fitzgerald
---------------------------------------
Edward M. Fitzgerald
Senior Vice President, Finance and Corporate
Operations, Chief Financial Officer
Date: July 9, 2007
3
EXHIBIT INDEX
-------------
Exhibit
Number Description
- ------ -----------
99.1 Press release dated July 9, 2007
4